-
Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated inflammatory responses that are associated with viral infections and inhibit viral replication in human lung cells. Its efficacy was successfully demonstrated during preclinical in vitro studies, where STAT-205 was able to inhibit the replication of…
You May Also Like
Biotricity Continues to Transform the Way We Do Health: Medtech Launches New Biokit Solution, Aims at Personal Health Monitoring
Is Generation Hemp Now A Leader in Pure-Play Hemp Operations for the Industrial Sector?
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
-
Terravis and the New Power Generation — Can it Solve the Infrastructure Dilemma in EVs?
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Committed to an all-green future and delivering power to places where it’s traditionally been out of reach, Worksport, Ltd (NASDAQ: WKSP) recently unveiled its top-secret plans to super-charge the future of electric vehicles (EVs), introducing the world to renewable and highly efficient hydrogen fuel-cell technologies through its upcoming EV fast-charging units and microgrid power structures. Through its newly established Terravis Energy Inc. subsidiary, Worksport takes off-grid power and mobility to a whole new level — boldly taking EVs where no other chargers could ever go before. High-Performance Hydrogen…
-
Industrial Hemp: Big Win for Pet Stores, Farmers, and Animals
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. According to the American Veterinary Medical Association, a common occurrence for sleep disorders in horses comes from environmental insecurity. Innovative hemp company Generation Hemp (OTCQB: GENH) is providing a new and effective way for companies and individuals with the need for animal bedding to have a better option. Animal lovers and investors alike are taking notice of Generation Hemp and its subsidiary Rowdy Rooster Hemp. An Example of How the Lack of Sleep Can Even Affect Horses “Pain or physical discomfort. Lyme disease. Environmental insecurity. Monotony. Aggression…
You May Also Like
Generation Hemp’s Green Policy is Inspired by a Cause, Executives Move From Oil and Gas to Industrial Green
Generation Hemp Reports Quarterly Financial Statements to SEC, Announces New Processing Contracts and Brand Launches
Why Is There a Renewed Interest in Hemp by Textile and Manufacturing Companies?
-
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
Previously Published on Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lineage Cell Therapeutics Inc. (AMEX: LCTX) recently provided an update on its lead program OpRegen®, a cell replacement therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). Lineage is pioneering a new branch of medicine, which is manufacturing differentiated cell types and transplanting those cells into the body, to restore or improve function which has been lost due to injury or disease. The data from an ongoing Phase 1/2a clinical study continued to demonstrate that a single administration of OpRegen, an investigational cell therapy consisting of…
-
6 Reasons Investors Should Consider Trading Share CFDs Over Trading Stocks
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Contracts for differences (CFDs), while prohibited in the United States, are extremely popular in other leading countries around the world. A CFD, as a derivative trade, is an agreement between 2 parties — usually the investor and the broker. In a CFD, the trade will be opened, and the exchange will occur between the opening and closing price of the contract — or the difference in the value of a security between an opening and closing price. Unlike options trading, investors have unlimited time…
